Clinical Trials Browser

Phase 1/2 × Malignant Solid Tumour × pembrolizumab × Clear all

NCT02843204 2020-05-28

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Malignant Solid Tumour